Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy

Core Viewpoint - Theratechnologies Inc. has announced the availability of EGRIFTA WR™ (tesamorelin) for injection, aimed at reducing excess abdominal fat in adult patients with HIV and lipodystrophy, following its approval by the U.S. FDA earlier this year [1][2]. Product Details - EGRIFTA WR™ offers a more convenient weekly reconstitution and requires less than half the injection volume compared to the previous formulation, EGRIFTA SV®, which required daily reconstitution [3]. - The new formulation is supplied as four single-patient-use vials, each containing 11.6 mg of tesamorelin, sufficient for seven daily injections, with a daily dose of 1.28 mg [3]. - EGRIFTA WR™ can be stored at room temperature (20° to 25° C [68° to 77° F]) before and after reconstitution, and its formulation is patent protected in the U.S. until 2033 [3]. Clinical Significance - The new formulation is the only medication approved in the U.S. for the reduction of excess abdominal fat in adults with HIV who have lipodystrophy, and it aims to simplify management and enhance user experience [2][4]. - Pharmacokinetic studies have shown bioequivalence of EGRIFTA WR™ to the original formulation of tesamorelin [4]. Transition Support - Individuals currently using EGRIFTA SV® can enroll in the Thera Patient Support® program to assist in transitioning to EGRIFTA WR™ as insurance coverage becomes available [5]. - The program includes a dedicated team of Thera Nurse Navigators to train enrolled patients on the use of EGRIFTA WR™ [5][6]. Company Overview - Theratechnologies is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that aim to redefine standards of care [10].